

Date: 10/02/2017

To

Deputy Manager  
Dept. of Corporate Services,  
Bombay Stock Exchange Limited  
P J Towers, Dalal Street,  
Fort, MUMBAI - 400001

Dear Sir/Madam,

Sub: Unaudited financial results for the quarter and Nine months ended on  
31<sup>st</sup> December, 2016

Ref: Reg. 33 of SEBI(Listing obligations and Disclosure Requirements)  
Regulations, 2015 Agreement, Script Code# 511509

With reference to subject cited above please find enclosed Unaudited financial results for the quarter and Nine months ended on 31<sup>st</sup> December, 2016, as per the Reg.33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Report issued by the Statutory Auditors of the company

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limited

M Kalyan Ram  
Whole Time Director  
DIN: 02012580



Statement of Unaudited Financial Results for the quarter and Nine months ended on 31st December, 2016							Rs. In Lacs
S.No.	PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31-Dec-16	30-Sep-16	31-Dec-15	31-Dec-16	31-Dec-15	31-Mar-16
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	a) Net Sales/ Income from Operations	841.91	891.85	784.99	2,357.08	2,116.81	2,851.90
	b) Other Operating Income	5.87	-	6.43	200.75	6.43	6.43
	<b>Total Income from operations</b>	<b>847.78</b>	<b>891.85</b>	<b>791.42</b>	<b>2,557.83</b>	<b>2,123.24</b>	<b>2,858.33</b>
2	Expenses						
	a. Increase/decrease in stock in trade and WIP	(142.85)	(81.59)	89.77	(102.04)	10.00	60.56
	b. Consumption of Raw materials	296.83	200.92	358.38	702.75	776.56	819.29
	c. Purchase of traded goods	-	-	-	-	-	-
	d. Employees Cost	133.06	137.15	107.99	401.89	306.91	434.26
	f. Other Expenditure	99.72	96.80	76.16	280.37	243.72	335.40
	g. Total	307.05	401.92	147.76	946.58	724.81	1,173.46
	<b>Profit/loss from Operations before other income, finance cost and exceptions items(1-2)</b>	<b>693.81</b>	<b>755.20</b>	<b>780.06</b>	<b>2,229.55</b>	<b>2,062.00</b>	<b>2,822.97</b>
3	Other income	153.97	136.65	11.35	328.27	61.24	35.36
4	Profit/(loss) from Ordinary activities before finance costs and exceptional items(3+4)	0.00	12.58	13.33	35.95	57.68	89.25
5	Finance costs	153.97	149.22	24.68	364.22	118.92	124.61
6	Profit/(loss) from Ordinary activities after finance costs but before exceptional items(5-6)	57.08	8.70	9.90	75.41	31.03	46.57
7	Exceptional items	96.89	140.52	14.77	288.82	87.89	78.04
8	Profit/Loss from Ordinary Activities before tax(7-8)	96.89	140.52	14.77	288.82	87.89	78.04
9	Tax Expense	24.22	25.02	4.43	60.56	26.37	(12.96)
10	Net Profit/Loss from Ordinary Activities after Tax(9-10)	72.67	115.50	10.34	228.26	61.52	91.00
11	Extraordinary Items (Net of Tax expense of Rs. ... Lakh)	-	-	-	-	-	-
12	Net Profit/Loss for the Period(11-12)	72.67	115.50	10.34	228.26	61.52	91.00
13	Paid Up Share Capital(Face Value of Rs. 10/-each items)	935.05	935.05	935.05	935.05	935.05	935.05
14	a) Basic	0.78	1.24	0.11	2.44	0.66	0.97
15	b) Diluted	0.78	1.24	0.11	2.44	0.66	0.97
15.i	Earning Per Share(EPS)(After Extraordinary items)	0.78	1.24	0.11	2.44	0.66	0.97
15.ii	a) Basic	0.78	1.24	0.11	2.44	0.66	0.97
15.iii	b) Diluted	0.78	1.24	0.11	2.44	0.66	0.97

Place: Hyderabad  
Date: 10th February, 2017

For Vivo Bio Tech Limited

M Kalyanaram  
Whole Time Director  
DIN : 02012580



Notes:

1. The above financial results are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 10<sup>th</sup> February, 2017.
2. The Figures for the quarter and nine months ended 31st December, 2016 was subjected to 'Limited Review' by Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with Bombay Stock Exchange and is also available on the company's website [www.vivobio.com](http://www.vivobio.com)
3. The Entire operations of the company relate to single segment viz., Bio Technology. Hence Segmental reporting as per AS-17 is not made.
4. Previous year's/period's figures are rearranged/ regrouped wherever necessary

Date: 10<sup>th</sup> February, 2017  
Place: Hyderabad

For Vivo Bio Tech Limited

  
M Kalyan Ram  
Whole Time Director  
DIN: 02012580







**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

To  
The Board of Directors  
**VIVO BIO TECH LIMITED**  
Hyderabad.

**Limited Review Report for Standalone Financials for the quarter ended 31<sup>st</sup> December, 2016**

1. We have reviewed the accompanying statement of unaudited Standalone financial results of **VIVO BIO TECH Limited** for the quarter ended 31<sup>st</sup> December, 2016, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 10<sup>th</sup> February, 2016. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI ( Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05<sup>th</sup> July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.  
Chartered Accountants  
FRN: 007257S

A Krishna Rao  
Partner

Membership Number. 020085



Place: Hyderabad

Date: 10<sup>th</sup> February, 2016